Published in Gene Therapy Weekly, December 25th, 2003
The development program will center on the recombinant immunotoxin SS1P. Enzon and the NCI plan to initially develop SS1P in pancreatic and ovarian carcinomas. Phase 2 trials are set to start in the second half of 2004.
This compound is currently in phase 1 clinical development at the U.S. National Cancer Institute (NCI) under the supervision of Dr....
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Gene Therapy Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.